BCLI Brainstorm Cell Therapeutics Inc
Price (delayed)
$0.2648
Market cap
$21.11M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.23
Enterprise value
$18.61M
BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases. The Company holds the rights to clinical development and commercialization of
Highlights
BCLI's debt has plunged by 71% YoY and by 14% from the previous quarter
The EPS has surged by 61% year-on-year and by 28% since the previous quarter
Key stats
What are the main financial stats of BCLI
Market
Valuations
Earnings
Shares outstanding
79.73M
Market cap
$21.11M
Enterprise value
$18.61M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$12.09M
EBITDA
-$11.83M
Free cash flow
-$14.46M
Per share
Balance sheet
Liquidity
EPS
-$0.23
Free cash flow per share
-$0.2
Book value per share
-$0.05
Revenue per share
$0
TBVPS
$0.08
Total assets
$5.68M
Total liabilities
$9.21M
Debt
$962,000
Equity
-$3.53M
Working capital
-$3.88M
Debt to equity
-0.27
Current ratio
0.5
Quick ratio
0.46
Net debt/EBITDA
0.21
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-269.5%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCLI stock price
How has the Brainstorm Cell Therapeutics stock price performed over time
Intraday
-6.1%
1 week
-4.4%
1 month
-22.23%
1 year
-72.54%
YTD
-3%
QTD
-21.77%
Financial performance
How have Brainstorm Cell Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$16.3M
Net income
-$12.75M
Gross margin
N/A
Net margin
N/A
The net income has increased by 43% YoY and by 18% QoQ
Brainstorm Cell Therapeutics's operating income has increased by 27% YoY and by 13% QoQ
Growth
What is Brainstorm Cell Therapeutics's growth rate over time
Valuation
What is Brainstorm Cell Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has surged by 61% year-on-year and by 28% since the previous quarter
The equity has grown by 36% from the previous quarter and by 9% YoY
Efficiency
How efficient is Brainstorm Cell Therapeutics business performance
The return on assets has increased by 18% since the previous quarter but it has declined by 7% year-on-year
Dividends
What is BCLI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCLI.
Financial health
How did Brainstorm Cell Therapeutics financials performed over time
Brainstorm Cell Therapeutics's total assets is 38% less than its total liabilities
Brainstorm Cell Therapeutics's current ratio has surged by 178% QoQ
Brainstorm Cell Therapeutics's total assets has soared by 70% from the previous quarter
BCLI's debt is 127% more than its equity
BCLI's debt has plunged by 71% YoY and by 14% from the previous quarter
The company's debt to equity has surged by 68% YoY but it fell by 35% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.